Unlike traditional clinical trials that evaluate one treatment at a time, the Beat AML Master Trial employs a novel approach called a master protocol. This allows multiple therapies to be tested simultaneously within the same trial framework. By leveraging genomic profiling, the trial identifies specific genetic mutations in patients' cancer cells and matches them with targeted therapies that are most likely to be effective.
